Welcome to our dedicated page for Tvardi Therapeutics news (Ticker: TVRD), a resource for investors and traders seeking the latest updates and insights on Tvardi Therapeutics stock.
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company whose news flow centers on the development of oral small molecule therapies targeting STAT3 for fibrosis-driven diseases and oncology indications. Company press releases consistently describe Tvardi as focused on STAT3, a transcription factor it identifies as a central mediator of fibrotic signaling pathways and as involved in cancer cell survival and immune evasion.
News updates for TVRD commonly cover progress in clinical trials of its lead STAT3 inhibitor TTI-101 and its next-generation STAT3 inhibitor TTI-109. Tvardi has issued detailed announcements on the REVERT IPF Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis, including completion of enrollment, preliminary data indicating that the study did not meet its goals, and subsequent analyses examining fibrosis scores, inflammatory markers such as IL-6, and pulmonary function measures like Forced Vital Capacity. Additional news highlights the REVERT Liver Cancer Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma and the initiation and progress of a healthy volunteer study of TTI-109.
Investors and followers of TVRD news can also expect regular financial and business updates, including quarterly results, cash runway disclosures, and commentary on upcoming clinical milestones. Tvardi frequently announces participation in healthcare and biotechnology investor conferences, such as events hosted by J.P. Morgan, Piper Sandler, Jefferies, Cantor and BTIG, where management provides corporate presentations and engages with investors.
This news page aggregates Tvardi’s press releases and related coverage so readers can track clinical trial developments, data readouts, regulatory milestones, and corporate communications related to its STAT3-targeted programs. For those monitoring TVRD stock, the news stream offers insight into how Tvardi’s clinical and corporate activities evolve over time.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, has announced its participation in two upcoming investor conferences. The company will join the Piper Sandler 3rd Annual Virtual Lung Symposium on May 27, 2025, at 11:30 AM ET for a fireside chat. Additionally, Tvardi will present at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 11:40 AM ET, which will include a corporate presentation and investor meetings. The Jefferies presentation will be available via webcast on Tvardi's Investors' website with a 60-day replay period.
Tvardi Therapeutics (NASDAQ: TVRD) announced its upcoming presentation at the American Thoracic Society 2025 Annual Conference in San Francisco. The presentation will highlight research on their STAT3 inhibitor, TTI-101, for treating idiopathic pulmonary fibrosis (IPF). Key findings show that ~60% of IPF-associated dysregulated genes are not addressed by current approved therapies (nintedanib and pirfenidone), termed the "IPF therapeutic gap." Research using single-cell RNA sequencing identified STAT3 as a dominant regulatory transcription factor in IPF. Notably, TTI-101 showed greater repression of genes within alveolar fibroblasts compared to existing treatments and demonstrated ability to downregulate genes involved in extracellular matrix production, including collagen genes.